89Zr-ss-pertuzumab Imaging for Breast Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug 89Zr-ss-pertuzumab for breast cancer?
Research shows that 89Zr-pertuzumab, a component of 89Zr-ss-pertuzumab, is effective in imaging HER2-positive breast cancer, helping to identify patients who may benefit from targeted therapies. It has been successful in detecting HER2-positive metastases even in patients with HER2-negative primary breast cancer, which can guide treatment decisions.12345
Is 89Zr-ss-pertuzumab safe for use in humans?
How does the drug 89Zr-ss-pertuzumab differ from other breast cancer treatments?
89Zr-ss-pertuzumab is unique because it is used for imaging rather than direct treatment, helping to identify HER2-positive breast cancer metastases that might not be detected by other methods. This drug is radiolabeled with zirconium-89, allowing it to be used in PET/CT scans to visualize cancer spread and assess HER2 status, which is crucial for determining the appropriate targeted therapy.12345
Research Team
Somali Gavane, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
This trial is for adults over 18 with HER2+ breast cancer, as defined by specific medical guidelines or genetic testing. Participants must have at least one detectable cancer lesion and be in fair to good physical condition (ECOG 0-2). Pregnant or breastfeeding individuals, those with certain kidney or liver conditions, a life expectancy under three months, or who exceed the weight limit for PET/CT scans cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 89Zr-ss-pertuzumab to evaluate its safety in HER2+ cancer
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- 89Zr-ss-pertuzumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
National Institutes of Health (NIH)
Collaborator